
Eric Schlumpf discusses why Stuart Therapeutics is taking vezocolmitide beyond dry eye disease and into corneal wound healing.

Eric Schlumpf is president and CEO of Stuart Therapeutics.

Eric Schlumpf discusses why Stuart Therapeutics is taking vezocolmitide beyond dry eye disease and into corneal wound healing.

Stuart Therapeutics presented preclinical data at OIS Retina 2026 on a non-gene-specific collagen mimetic peptide that preserved retinal thickness and visual function in 2 mouse models of inherited retinal disease.